[Form 4] Spyre Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. reported that its Chief Medical Officer, Sloan Sheldon, received a stock option grant on January 9, 2026. The award covers options to purchase 140,000 shares of Spyre’s common stock at an exercise price of $30.61 per share, expiring on January 9, 2036. Following this grant, Sloan Sheldon beneficially owns 140,000 stock options directly. The option will vest in equal monthly installments over four years, conditioned on continued employment with the company at each vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sloan Sheldon

(Last) (First) (Middle)

221 CRESCENT STREET, BUILDING 23

SUITE 105

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$30.61	01/09/2026		A		140,000		(1)	01/09/2036	Common Stock	140,000	$0	140,000	D

Explanation of Responses:

1. This option represents a right to purchase 140,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Spyre Therapeutics (SYRE) report in this Form 4?

Spyre Therapeutics reported a stock option grant to Chief Medical Officer Sloan Sheldon for 140,000 options to buy common stock.

What is the exercise price and expiration date of Sloan Sheldon's Spyre options?

The stock options have an exercise price of $30.61 per share and an expiration date of January 9, 2036.

How many Spyre Therapeutics shares underlie Sloan Sheldon's stock option grant?

The option represents the right to purchase 140,000 shares of Spyre Therapeutics common stock.

What is Sloan Sheldon's role at Spyre Therapeutics (SYRE)?

Sloan Sheldon is an officer of Spyre Therapeutics, serving as the company’s Chief Medical Officer.

How does the vesting schedule work for Sloan Sheldon's Spyre stock options?

The 140,000-share option vests in equal monthly installments over four years, subject to Sloan Sheldon's continued employment on each vesting date.

How many Spyre stock options does Sloan Sheldon own after this transaction?

After this grant, Sloan Sheldon beneficially owns 140,000 stock options in Spyre Therapeutics, held as direct ownership.